Malformin-A1 (MA1) Sensitizes Chemoresistant Ovarian Cancer Cells to Cisplatin-Induced Apoptosis
Authors:
- Nada AbdullahNada Abdullah
- Yahya TamimiYTYahya Tamimi
- Sergey DobretsovSDSergey Dobretsov
- Najwa Al BalushiNBNajwa Al Balushi
- Jalila AlshekailiJAJalila Alshekaili
- Hamed Al BalushiHBHamed Al Balushi
- Mahmood Al KindiMKMahmood Al Kindi
- Syed Imran HassanSHSyed Imran Hassan
- Shadia Al BahlaniSBShadia Al Bahlani
- Benjamin K. TsangBTBenjamin K. Tsang
- Ikram A. BurneyIBIkram A. Burney
Open Access
Abstract
High-grade epithelial ovarian cancer is a fatal disease in women frequently associated with drug resistance and poor outcomes. We previously demonstrated that a marine-derived compound MalforminA1 (MA1) was cytotoxic for the breast cancer cell line MCF-7. In this study, we aimed to examine the effect of MA1 on human ovarian cancer cells. The potential cytotoxicity of MA1was tested on cisplatin-sensitive (A2780S) and cisplatin-resistant (A2780CP) ovarian cancer cell lines using AlamarBlue assay, Hoechst dye, flow cytometry, Western blot, and RT-qPCR. MA1 had higher cytotoxic activity on A2780S (IC50 = 0.23 µM) and A2780CP (IC50 = 0.34 µM) cell lines when compared to cisplatin (IC50 = 31.4 µM and 76.9 µM, respectively). Flow cytometry analysis confirmed the cytotoxic effect of MA1. The synergistic effect of the two drugs was obvious, since only 13% of A2780S and 7% of A2780CP cells remained alive after 24 h of treatment with both MA1 and cisplatin. Moreover, we examined the expression of bcl2, p53, caspase3/9 genes at RNA and protein levels using RT-qPCR and Western blot, respectively, to figure out the cell death mechanism induced by MA1. A significant down-regulation in bcl2 and p53 genes was observed in treated cells compared to non-treated cells (p < 0.05), suggesting that MA1 may not follow the canonical pathway to induce apoptosis in ovarian cancer cell lines. MalforminA1 showed promising anticancer activity by inducing cytotoxicity in cisplatin-sensitive and cisplatin-resistant cancer cell lines. Interestingly, a synergistic effect was observed when MA1 was combined with cisplatin, leading to it overcoming its resistance to cisplatin.Keywords
This publication has 37 references indexed in Scilit:
- Pharmacological Inhibition of LIM Kinase Stabilizes Microtubules and Inhibits Neoplastic GrowthCancer Research, 2012
- Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian CancerNew England Journal of Medicine, 2012
- Akt2 Kinase Suppresses Glyceraldehyde-3-phosphate Dehydrogenase (GAPDH)-mediated Apoptosis in Ovarian Cancer Cells via Phosphorylating GAPDH at Threonine 237 and Decreasing Its Nuclear TranslocationJournal of Biological Chemistry, 2011
- Caspase 3–mediated stimulation of tumor cell repopulation during cancer radiotherapyNature Medicine, 2011
- Gene Expression Profile of BRCAness That Correlates With Responsiveness to Chemotherapy and With Outcome in Patients With Epithelial Ovarian CancerJournal of Clinical Oncology, 2010
- Combination versus sequential cytotoxic chemotherapy in recurrent ovarian cancer: Time for an evidence-based comparisonGynecologic Oncology, 2010
- Mutant p53 Gain-of-Function in CancerCold Spring Harbor Perspectives in Biology, 2009
- Novel roles for GAPDH in cell death and carcinogenesisCell Death & Differentiation, 2009
- Asperpyrone D and other metabolites of the plant-associated fungal strain Aspergillus tubingensisPhytochemistry, 2007
- Involvement of the bcl -2 Gene in Human Follicular LymphomaScience, 1985